Symbols / LNTH Stock $93.91 -2.86% Lantheus Holdings, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NGM
LNTH (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Ms. Mary Anne Heino
Exch · Country NGM · United States
Market Cap 6.11B
Enterprise Value 6.24B
Income 279.03M
Sales 1.55B
FCF (ttm) 421.71M
Book/sh 18.63
Cash/sh 7.66
Employees 1,193
Insider 10d —
IPO Jun 25, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 22.41
Forward P/E 14.73
PEG —
P/S 3.95
P/B 5.04
P/C —
EV/EBITDA 17.04
EV/Sales 4.04
Quick Ratio 2.57
Current Ratio 2.83
Debt/Eq 51.62
LT Debt/Eq —
EPS (ttm) 4.19
EPS next Y 6.37
EPS Growth 76.50%
Revenue Growth 1.20%
EPS Gr Q/Q 62.30%
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-07
ROA 8.15%
ROE 23.48%
ROIC —
Gross Margin 60.48%
Oper. Margin 21.65%
Profit Margin 18.05%
Shs Outstand 65.11M
Shs Float 58.57M
Insider Own 2.03%
Instit Own 112.87%
Short Float 11.60%
Short Ratio 8.19
Short Interest 5.67M
52W High 98.27
vs 52W High -4.44%
52W Low 47.25
vs 52W Low 98.75%
Beta -0.08
Impl. Vol. 40.28%
Rel Volume 0.93
Avg Volume 980.77K
Volume 913.09K
Target (mean) $104.08
Tgt Median $105.00
Tgt Low $76.00
Tgt High $117.00
# Analysts 13
Recom Strong_buy
Prev Close $96.67
Price $93.91
Change -2.86%
About

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$104.08
Mean price target
2. Current target
$93.91
Latest analyst target
3. DCF / Fair value
$116.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$93.91
Low
$76.00
High
$117.00
Mean
$104.08

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 reit Truist Securities Buy → Buy $115
2026-05-08 main Citizens Market Outperform → Market Outperform $115
2026-05-08 main Mizuho Outperform → Outperform $100
2026-04-15 main Truist Securities Buy → Buy $98
2026-04-13 main Mizuho Outperform → Outperform $95
2026-03-02 main Truist Securities Buy → Buy $89
2026-02-27 main Mizuho Outperform → Outperform $85
2026-02-27 main Citizens Market Outperform → Market Outperform $85
2026-02-27 down Jones Trading Buy → Hold —
2026-02-24 main Citizens Market Outperform → Market Outperform $78
2025-12-18 main Truist Securities Buy → Buy $82
2025-12-17 main Mizuho Outperform → Outperform $72
2025-12-12 up Truist Securities Hold → Buy $80
2025-11-10 reit Truist Securities Hold → Hold $61
2025-10-08 down Goldman Sachs Buy → Neutral $77
2025-09-16 main B. Riley Securities Buy → Buy $84
2025-09-15 main TD Cowen Buy → Buy $80
2025-08-12 down Truist Securities Buy → Hold $63
2025-08-07 main JMP Securities Market Outperform → Market Outperform $73
2025-08-07 main Mizuho Outperform → Outperform $70
News
RSS: Latest LNTH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-05 MARSHALL ROBERT J. JR. Chief Financial Officer — 38,002 $0.00 $0
2026-03-05 NIEDZWIECKI DANIEL M. General Counsel — 36,692 $0.00 $0
2026-03-05 MORGAN AMANDA MICHELLE Officer — 26,208 $0.00 $0
2026-03-05 BROWN KIMBERLY Officer — 6,158 $0.00 $0
2026-03-05 DINKELBORG LUDGER Officer — 20,966 $0.00 $0
2026-03-02 MARSHALL ROBERT J. JR. Chief Financial Officer — 8,491 $0.00 $0
2026-03-02 NIEDZWIECKI DANIEL M. General Counsel — 5,169 $0.00 $0
2026-03-02 MORGAN AMANDA MICHELLE Officer — 2,782 $0.00 $0
2026-03-02 HEINO MARY ANNE Chief Executive Officer — 32,105 $0.00 $0
2025-11-17 HEINO MARY ANNE Officer and Director — 14,285 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,541.61
+0.50%
1,533.91
+18.32%
1,296.43
+38.65%
935.06
Operating Revenue
1,541.61
+0.50%
1,533.91
+18.32%
1,296.43
+38.65%
935.06
Cost Of Revenue
599.66
+9.90%
545.62
-7.03%
586.89
+66.09%
353.36
Reconciled Cost Of Revenue
599.66
+9.90%
545.62
-7.03%
586.89
+66.09%
353.36
Gross Profit
941.95
-4.69%
988.29
+39.29%
709.54
+21.98%
581.70
Operating Expense
626.39
+16.06%
539.73
+56.49%
344.90
-36.77%
545.51
Research And Development
177.31
+5.48%
168.10
+116.32%
77.71
-75.07%
311.68
Selling General And Administration
453.81
+22.11%
371.63
+39.09%
267.19
+14.27%
233.83
Selling And Marketing Expense
178.69
+0.42%
177.94
+25.54%
141.74
+41.39%
100.24
General And Administrative Expense
275.12
+42.04%
193.69
+54.39%
125.46
-6.08%
133.58
Other Gand A
275.12
+42.04%
193.69
+54.39%
125.46
-6.08%
133.58
Other Operating Expenses
-4.73
—
—
—
Total Expenses
1,226.05
+12.96%
1,085.35
+16.48%
931.79
+3.66%
898.87
Operating Income
315.56
-29.65%
448.56
+23.01%
364.64
+907.44%
36.20
Total Operating Income As Reported
310.83
-31.98%
456.98
+25.32%
364.64
+907.44%
36.20
EBITDA
403.64
-21.66%
515.27
+4.94%
491.00
+500.01%
81.83
Normalized EBITDA
409.00
-25.78%
551.05
+24.06%
444.18
+412.10%
86.74
Reconciled Depreciation
70.10
+8.47%
64.62
+7.63%
60.04
+25.27%
47.93
EBIT
333.54
-25.99%
450.65
+4.57%
430.96
+1171.12%
33.90
Total Unusual Items
-5.36
+85.03%
-35.78
-176.40%
46.83
+1054.83%
-4.90
Total Unusual Items Excluding Goodwill
-5.36
+85.03%
-35.78
-176.40%
46.83
+1054.83%
-4.90
Special Income Charges
4.27
-49.94%
8.52
-81.81%
46.85
+1107.87%
-4.65
Other Special Charges
0.73
+792.45%
-0.11
-102.14%
4.94
+6.35%
4.65
Net Income
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Pretax Income
313.79
-27.19%
430.98
+4.88%
410.94
+1438.02%
26.72
Net Non Operating Interest Income Expense
3.64
-78.79%
17.17
+4606.30%
-0.38
+91.67%
-4.57
Interest Expense Non Operating
19.75
+0.41%
19.67
-1.75%
20.02
+178.62%
7.18
Net Interest Income
3.64
-78.79%
17.17
+4606.30%
-0.38
+91.67%
-4.57
Interest Expense
19.75
+0.41%
19.67
-1.75%
20.02
+178.62%
7.18
Interest Income Non Operating
23.39
-36.50%
36.84
+87.59%
19.64
+651.55%
2.61
Interest Income
23.39
-36.50%
36.84
+87.59%
19.64
+651.55%
2.61
Other Income Expense
-5.41
+84.44%
-34.76
-174.45%
46.68
+1051.92%
-4.90
Other Non Operating Income Expenses
-0.05
-105.10%
1.02
+813.29%
-0.14
—
Gain On Sale Of Security
-9.62
+78.28%
-44.30
-210838.10%
-0.02
+91.80%
-0.26
Tax Provision
80.23
-32.31%
118.53
+40.64%
84.28
+6352.37%
-1.35
Tax Rate For Calcs
0.00
-6.91%
0.00
+34.15%
0.00
-2.38%
0.00
Tax Effect Of Unusual Items
-1.37
+86.06%
-9.84
-202.49%
9.60
+1032.10%
-1.03
Net Income Including Noncontrolling Interests
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Net Income From Continuing Operation Net Minority Interest
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Net Income From Continuing And Discontinued Operation
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Net Income Continuous Operations
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Normalized Income
237.54
-29.80%
338.38
+16.91%
289.44
+806.15%
31.94
Net Income Common Stockholders
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Diluted EPS
3.41
-21.79%
4.36
-6.24%
4.65
+1062.50%
0.40
Basic EPS
3.46
-23.45%
4.52
-5.64%
4.79
+1068.29%
0.41
Basic Average Shares
67.49
-2.47%
69.20
+1.37%
68.27
-0.32%
68.49
Diluted Average Shares
68.44
-4.48%
71.65
+2.01%
70.24
-0.61%
70.67
Diluted NI Availto Com Stockholders
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Gain On Sale Of PPE
5.00
-40.58%
8.41
-83.75%
51.79
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,227.40
+12.48%
1,980.34
+19.94%
1,651.15
+24.97%
1,321.26
Current Assets
899.96
-32.16%
1,326.63
+22.18%
1,085.82
+60.24%
677.62
Cash Cash Equivalents And Short Term Investments
359.12
-60.66%
912.81
+27.91%
713.66
+71.70%
415.65
Cash And Cash Equivalents
359.12
-60.66%
912.81
+27.91%
713.66
+71.70%
415.65
Receivables
374.03
+13.54%
329.44
+15.88%
284.29
+33.22%
213.40
Accounts Receivable
358.64
+11.64%
321.26
+13.00%
284.29
+33.22%
213.40
Gross Accounts Receivable
368.14
+11.88%
329.06
—
—
Allowance For Doubtful Accounts Receivable
-9.50
-21.79%
-7.80
—
—
Taxes Receivable
15.39
+88.17%
8.18
—
—
Inventory
64.67
-4.93%
68.03
+6.24%
64.03
+80.49%
35.48
Raw Materials
25.93
-10.84%
29.08
-6.97%
31.26
+56.40%
19.99
Work In Process
16.34
+2.93%
15.87
+14.94%
13.81
+67.68%
8.23
Finished Goods
22.41
-2.87%
23.07
+21.68%
18.96
+161.41%
7.25
Prepaid Assets
20.75
+34.69%
15.41
-6.27%
16.44
+27.55%
12.89
Assets Held For Sale Current
80.74
0.00
-100.00%
7.16
0.00
Other Current Assets
0.65
-31.79%
0.95
+287.40%
0.25
+20.00%
0.20
Total Non Current Assets
1,327.43
+103.06%
653.71
+15.63%
565.33
-12.17%
643.64
Net PPE
194.66
-8.56%
212.88
+10.86%
192.02
+35.99%
141.20
Gross PPE
267.45
-16.85%
321.64
+7.56%
299.05
+23.92%
241.33
Accumulated Depreciation
-72.79
+33.07%
-108.76
-1.62%
-107.02
-6.89%
-100.13
Properties
0.00
0.00
0.00
0.00
Land And Improvements
3.02
-68.14%
9.48
+0.00%
9.48
-29.52%
13.45
Buildings And Improvements
49.91
-41.64%
85.52
+16.45%
73.44
-3.78%
76.33
Machinery Furniture Equipment
166.14
+1.89%
163.06
+25.59%
129.84
+9.59%
118.47
Construction In Progress
17.41
-36.70%
27.50
-32.87%
40.96
+191.62%
14.05
Other Properties
30.98
-14.16%
36.08
-20.39%
45.33
+138.14%
19.03
Goodwill And Other Intangible Assets
962.30
+331.62%
222.95
+4.59%
213.17
-43.38%
376.47
Goodwill
239.52
+291.44%
61.19
+0.00%
61.19
+0.00%
61.19
Other Intangible Assets
722.78
+346.82%
161.76
+6.43%
151.99
-51.79%
315.29
Investments And Advances
42.21
+6.90%
39.49
0.00
—
Non Current Deferred Assets
109.20
-35.85%
170.23
+13.34%
150.20
+35.75%
110.65
Non Current Deferred Taxes Assets
109.20
-35.85%
170.23
+13.34%
150.20
+35.75%
110.65
Other Non Current Assets
19.07
+133.86%
8.15
-17.93%
9.94
-35.15%
15.32
Total Liabilities Net Minority Interest
1,137.60
+27.49%
892.33
+6.83%
835.26
-4.44%
874.11
Current Liabilities
333.42
+38.62%
240.53
+28.38%
187.35
-24.36%
247.70
Payables And Accrued Expenses
228.40
+26.26%
180.89
+30.81%
138.29
+50.81%
91.70
Payables
46.48
+28.57%
36.15
-12.23%
41.19
+100.31%
20.56
Accounts Payable
42.91
+24.15%
34.56
-16.09%
41.19
+100.31%
20.56
Current Accrued Expenses
181.92
+25.69%
144.74
+49.06%
97.10
+36.50%
71.13
Pensionand Other Post Retirement Benefit Plans Current
63.24
+31.04%
48.26
+32.84%
36.33
+19.41%
30.43
Total Tax Payable
3.57
+124.64%
1.59
—
—
Income Tax Payable
3.57
+124.64%
1.59
—
—
Current Debt And Capital Lease Obligation
0.74
-24.23%
0.97
+18.35%
0.82
+132.49%
0.35
Current Debt
0.74
-24.23%
0.97
+18.35%
0.82
+132.49%
0.35
Other Current Liabilities
41.04
+294.72%
10.40
-12.67%
11.91
-90.49%
125.22
Total Non Current Liabilities Net Minority Interest
804.18
+23.38%
651.80
+0.60%
647.91
+3.43%
626.41
Long Term Debt And Capital Lease Obligation
618.69
+0.04%
618.46
+0.38%
616.12
+5.65%
583.15
Long Term Debt
568.68
+0.60%
565.28
+0.64%
561.67
+0.71%
557.71
Long Term Capital Lease Obligation
50.02
-5.96%
53.19
-2.33%
54.45
+114.03%
25.44
Long Term Provisions
0.14
-99.41%
23.34
+1.87%
22.92
+1.65%
22.54
Non Current Deferred Liabilities
54.25
0.00
—
—
Non Current Deferred Taxes Liabilities
54.25
0.00
—
—
Other Non Current Liabilities
131.10
+1211.71%
9.99
+12.71%
8.87
-57.19%
20.71
Stockholders Equity
1,089.80
+0.16%
1,088.01
+33.35%
815.89
+82.47%
447.15
Common Stock Equity
1,089.80
+0.16%
1,088.01
+33.35%
815.89
+82.47%
447.15
Capital Stock
0.72
+1.27%
0.71
+1.43%
0.70
+1.45%
0.69
Common Stock
0.72
+1.27%
0.71
+1.43%
0.70
+1.45%
0.69
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
71.83
+1.30%
70.91
+1.49%
69.86
+1.47%
68.85
Ordinary Shares Number
64.59
-5.64%
68.45
-0.11%
68.52
+1.50%
67.51
Treasury Shares Number
7.24
+194.95%
2.46
+83.35%
1.34
+0.00%
1.34
Additional Paid In Capital
888.32
+8.60%
817.97
+7.95%
757.73
+5.85%
715.88
Retained Earnings
679.50
+52.37%
445.94
+234.03%
133.50
+169.12%
-193.16
Gains Losses Not Affecting Retained Earnings
-1.31
+19.07%
-1.61
-55.74%
-1.04
+17.63%
-1.26
Treasury Stock
477.44
+172.82%
175.00
+133.33%
75.00
+0.00%
75.00
Other Equity Adjustments
-1.31
+19.07%
-1.61
-55.74%
-1.04
+17.63%
-1.26
Total Equity Gross Minority Interest
1,089.80
+0.16%
1,088.01
+33.35%
815.89
+82.47%
447.15
Total Capitalization
1,658.47
+0.31%
1,653.29
+20.02%
1,377.56
+37.09%
1,004.86
Working Capital
566.54
-47.84%
1,086.11
+20.88%
898.47
+108.99%
429.92
Invested Capital
1,659.21
+0.30%
1,654.26
+20.01%
1,378.38
+37.12%
1,005.21
Total Debt
619.43
0.00%
619.44
+0.40%
616.95
+5.73%
583.51
Net Debt
210.29
—
—
142.41
Capital Lease Obligations
50.02
-5.96%
53.19
-2.33%
54.45
+114.03%
25.44
Net Tangible Assets
127.50
-85.26%
865.06
+43.53%
602.72
+752.83%
70.67
Tangible Book Value
127.50
-85.26%
865.06
+43.53%
602.72
+752.83%
70.67
Available For Sale Securities
42.21
+6.90%
39.49
—
—
Investmentin Financial Assets
42.21
+6.90%
39.49
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
390.14
-28.38%
544.75
+78.45%
305.26
+8.33%
281.78
Cash Flow From Continuing Operating Activities
390.14
-28.38%
544.75
+78.45%
305.26
+8.33%
281.78
Net Income From Continuing Operations
233.56
-25.25%
312.44
-4.35%
326.66
+1063.86%
28.07
Depreciation Amortization Depletion
70.10
+8.47%
64.62
+7.63%
60.04
+25.27%
47.93
Depreciation
70.10
+8.47%
64.62
+7.63%
60.04
+25.27%
47.93
Depreciation And Amortization
70.10
+8.47%
64.62
+7.63%
60.04
+25.27%
47.93
Other Non Cash Items
22.22
-72.15%
79.79
+66592.50%
-0.12
-100.04%
300.29
Stock Based Compensation
85.56
+12.00%
76.39
+51.25%
50.51
+72.60%
29.26
Provisionand Write Offof Assets
2.20
+343.58%
-0.90
-111.42%
7.91
+10.76%
7.14
Asset Impairment Charge
-4.73
0.00
-100.00%
138.05
0.00
Deferred Tax
21.84
+188.09%
-24.79
+54.76%
-54.81
-7.59%
-50.94
Deferred Income Tax
21.84
+188.09%
-24.79
+54.76%
-54.81
-7.59%
-50.94
Operating Gains Losses
-5.00
+40.58%
-8.41
+83.75%
-51.79
-955.63%
-4.91
Gain Loss On Investment Securities
—
—
—
-5.49
Unrealized Gain Loss On Investment Securities
8.62
-80.22%
43.56
0.00
0.00
Gain Loss On Sale Of PPE
-5.00
0.00
+100.00%
-51.79
0.00
Change In Working Capital
-44.23
-2259.86%
2.05
+101.20%
-171.20
-128.07%
-75.06
Change In Receivables
-17.89
+52.53%
-37.69
+45.10%
-68.64
+46.57%
-128.46
Changes In Account Receivables
-17.89
+52.53%
-37.69
+45.10%
-68.64
+46.57%
-128.46
Change In Inventory
-9.37
-250.79%
-2.67
+92.63%
-36.22
-382.42%
-7.51
Change In Payables And Accrued Expense
-11.57
-130.49%
37.96
+159.39%
-63.92
-200.08%
63.88
Change In Accrued Expense
-9.08
-119.42%
46.77
+157.66%
-81.11
-227.59%
63.58
Change In Payable
-2.49
+71.69%
-8.80
-151.22%
17.19
+5610.63%
0.30
Change In Account Payable
-2.49
+71.69%
-8.80
-151.22%
17.19
+5610.63%
0.30
Change In Other Current Assets
-5.41
-221.76%
4.44
+283.62%
-2.42
+18.67%
-2.97
Investing Cash Flow
-627.17
-177.49%
-226.01
-3905.61%
5.94
+102.15%
-276.55
Cash Flow From Continuing Investing Activities
-627.17
-177.49%
-226.01
-3905.61%
5.94
+102.15%
-276.55
Capital Expenditure
-41.50
+47.88%
-79.62
-71.03%
-46.55
-153.75%
-18.35
Capital Expenditure Reported
-36.09
+30.09%
-51.62
-10.89%
-46.55
-153.75%
-18.35
Net Business Purchase And Sale
-585.67
-603.54%
-83.25
0.00
0.00
Purchase Of Business
-585.67
-603.54%
-83.25
0.00
0.00
Net Intangibles Purchase And Sale
-5.41
+80.67%
-28.00
0.00
0.00
Purchase Of Intangibles
-5.41
+80.67%
-28.00
0.00
0.00
Net Other Investing Changes
—
-63.14
-220.29%
52.49
+120.33%
-258.20
Financing Cash Flow
-316.58
-167.08%
-118.54
-807.49%
-13.06
-104.19%
311.69
Cash Flow From Continuing Financing Activities
-316.58
-167.08%
-118.54
-807.49%
-13.06
-104.19%
311.69
Net Issuance Payments Of Debt
-1.11
-249.06%
-0.32
+55.65%
-0.72
-100.19%
382.37
Issuance Of Debt
—
0.00
0.00
-100.00%
557.75
Repayment Of Debt
-1.11
-249.06%
-0.32
+55.65%
-0.72
+99.59%
-175.38
Long Term Debt Issuance
—
0.00
0.00
-100.00%
557.75
Long Term Debt Payments
-1.11
-249.06%
-0.32
+55.65%
-0.72
+99.59%
-175.38
Net Long Term Debt Issuance
-1.11
-249.06%
-0.32
+55.65%
-0.72
-100.19%
382.37
Net Common Stock Issuance
-296.29
-206.88%
-96.55
-5094.83%
1.93
+102.63%
-73.62
Common Stock Payments
-300.02
-200.02%
-100.00
0.00
+100.00%
-75.00
Repurchase Of Capital Stock
-300.02
-200.02%
-100.00
0.00
+100.00%
-75.00
Proceeds From Stock Option Exercised
7.15
+118.24%
3.28
-14.10%
3.82
-49.37%
7.54
Net Other Financing Charges
-26.34
-5.58%
-24.95
-37.87%
-18.09
-294.55%
-4.59
Changes In Cash
-553.61
-376.53%
200.20
-32.85%
298.14
-5.93%
316.93
Effect Of Exchange Rate Changes
-0.05
+95.09%
-1.00
-973.12%
-0.09
+72.24%
-0.34
Beginning Cash Position
914.49
+27.85%
715.28
+71.43%
417.24
+314.54%
100.65
End Cash Position
360.83
-60.54%
914.49
+27.85%
715.28
+71.43%
417.24
Free Cash Flow
348.64
-25.04%
465.12
+79.79%
258.70
-1.80%
263.43
Interest Paid Supplemental Data
15.09
+0.00%
15.09
-1.90%
15.39
+203.85%
5.06
Income Tax Paid Supplemental Data
69.04
-55.12%
153.81
+1.48%
151.58
+180.45%
54.05
Common Stock Issuance
3.73
+8.03%
3.45
+78.48%
1.93
+40.58%
1.38
Issuance Of Capital Stock
3.73
+8.03%
3.45
+78.48%
1.93
+40.58%
1.38
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category